

Pfizer Inc. Specialty Care Business Review

ADVANCING SCIENCE  IMPROVING LIVES

Geno Germano
President & General Manager
Specialty Care Business Unit

**Goldman-Sachs
Healthcare Conference**

June 15, 2010



Forward-Looking Statements and Non-GAAP Financial Information


- Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer's 2009 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.
- Also, the discussions during this presentation will include certain financial measures that were not prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer's Current Report on Form 8-K dated May 4, 2010.
- These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section.

SCBU Significantly Contributes to the Worldwide Biopharmaceutical Businesses

- **Strong portfolio of inline and pipeline assets**
 - ◆ More than 20 products spanning 11 disease areas
 - ◆ Low near-term patent expiry exposure relative to the size of the overall business
 - ◆ Significant and growing presence in Vaccines
 - ◆ Strong late-stage pipeline, including two highly valued development programs (Pprevnar 13 adult, tasocitinib)
- **SCBU is responsible for development beyond proof-of concept and is committed to developing a portfolio of highly valued products for patients**
- **SCBU enhances Pfizer diversification by successfully operating in various go-to market models across the Specialty Pharma landscape**
- **Managed as an independent BU with profit/loss responsibility and accountability within the Biopharmaceutical segment**


Pfizer is the Number One Specialty Care Company in the World

Specialty Care's Broad In-line Portfolio and Pipeline Span 11 Disease Areas



Prevenar 13 Platform: *A Projected Growth Driver for Pfizer*

PREVENAR 13 – Coverage of the 13 most prevalent serotypes worldwide³



BUILT ON THE SCIENTIFIC FOUNDATION OF PREVENAR

- Provides the broadest coverage of any pneumococcal conjugate vaccine
- Approved for pediatric use in over 50 countries
- Have entered into agreement with GAVI to improve access to Prevenar 13 in the developing world

Prevnar 13 Adult: *Another Important Healthcare Opportunity*

High Incidence

- IPD incidence in adults >50 approaches incidence in children <5
- Pneumococcal pneumonia >500,000 cases/year in the US

Significant Unmet Need

- IPD and Pneumococcal Pneumonia are associated with mortality and significant morbidity
- Existing polysaccharide vaccine has limitations

Excellent Profile

- Building on the scientific foundation of Prevnar
- Potential to become the standard of care for the long-term prevention of pneumococcal disease

Significantly Expand the Prevnar Franchise by Offering Effective and Long-Term PD Prevention to Adults

Pfizer Specialty Care Supports Other Key Development Initiatives Across Disease Areas

Tasocitinib (Inflammation)

- Novel MOA inhibiting the Jak Kinase inflammation pathway
- Large unmet medical need across multiple indications
- Potential to offer biologic-like efficacy in a tablet

Comprehensive Ph III program is underway for Tasocitinib in Rheumatoid Arthritis across 6 trials

Bapineuzumab * (Alzheimer's Disease)

- Potential for disease modification in mild-to-moderate Alzheimer's Disease
- Acts to clear beta-amyloid & beta-amyloid plaques
- Potential to reduce rate of decline in cognitive and functional status

Currently, four Ph III studies in over 4,000 patients worldwide

* A collaboration with Janssen Alzheimer Immunotherapy

Xiapex (Dupuytren's)

- Significant unmet need for less invasive treatments
- Clinically proven profile

Approved in the US (as Xiaflex). A novel, first-in-class, biologic for adult Dupuytren's contracture patients with a palpable cord*

* Pfizer has rights in 27 EU and 19 Eurasian countries

Pfizer Specialty Care Provides Fertile Ground for Growth Organically and through BD

Strong Growth Potential in Key Disease Areas with Robust Substrate and Capabilities

The Diverse Landscape Creates Opportunity to Excel in Many Different Areas

Business Development viewed as an enabler of SCBU Strategy

Our Broad Capabilities Across a Range of Business Models Position SCBU to Seize Numerous Opportunities

Pfizer Inc. Specialty Care Business Review

ADVANCING SCIENCE  IMPROVING LIVES

Geno Germano
President & General Manager
Specialty Care Business Unit

**Goldman-Sachs
Healthcare Conference**

June 15, 2010

